Clinical Trials Browser

Phase 3 × INDUSTRY × ruxolitinib × Clear all

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04472598 2025-02-21

TRANSFORM-1

Phase 3 Completed

252 enrolled

Myeloid

Neoplasms, Primary Myelofibrosis

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Lymphoid

Pathologic Complete Response, Lymphoma, Follicular

NCT02038036 2021-07-20

RESPONSE-2

Phase 3 Completed

149 enrolled 19 charts

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Myeloid

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02117479 2019-03-26

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Phase 3 Terminated

321 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Phase 3 Completed

222 enrolled 21 charts

Myeloid

Polycythemia Vera

NCT00952289 2018-03-12

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Phase 3 Completed

309 enrolled 18 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02119663 2018-02-13

A Study of Ruxolitinib in Pancreatic Cancer Patients

Phase 3 Terminated

86 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

SENTRY

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

TRANSFORM-1

2002

RESPONSE-2

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

A Study of Ruxolitinib in Pancreatic Cancer Patients